Navigation Links
TGen findings contribute to understanding of diabetic kidney disease
Date:4/22/2011

PHOENIX, Ariz.-- April 22, 2011-- A gene called PVT1 may help reduce the kidneys ability to filter blood, leading to kidney disease, kidney failure and death, according to a study published today by researchers at the Translational Genomics Research Institute (TGen).

The TGen team found PVT1 expression levels increased up to 5-fold in response to hyperglycemia, or high blood sugar, a condition that often accompanies diabetes.

But by knocking down or reducing the expression of the PVT1gene, TGen researchers lowered the amount of proteins associated with the excessive accumulation of extracellular matrix (ECM) in glomeruli, part of the basic filtration unit of kidneys, according to the TGen study published today in the online scientific journal Public Library of Science (PLoS) ONE.

The accumulation of excessive ECM within the mesangial cells, which regulate blood flow in capillaries inside the kidney, is a hallmark of diabetic nephropathy, or kidney disease, which is the leading cause of reduced life expectancy among the nation's growing numbers of diabetics.

"The goal of this study was to identify possible molecular mechanisms by which PVT1 may contribute to the development and progression of diabetic nephropathy in mesangial cells," said Dr. Johanna DiStefano, the study's senior author and Director of TGen's Diabetes, Cardiovascular and Metabolic Diseases Center.

"Despite the growing magnitude of the disease, the molecular mechanisms underlying the etiology of diabetic nephropathy remain poorly understood," Dr. DiStefano said.

PVT1, also known as plasmacytoma variant translocation 1, was previously identified by Dr. DiStefano's team as a candidate gene for End Stage Renal Disease (ESRD), or kidney failure. Too much PVT1 also has been associated with breast and ovarian cancers, in which it may help cause cells to multiply out of control and fail to go through the normal process of cellular death.

Through RNA interference, which helps control which genes are active and the degree of their activity, researchers reduced the expression of PVT1, which in turn reduced the protein levels of ECM components.

In a related finding, TGen scientists discovered that PVT1 affects the expression of other genes FN1, COL4A1 and PAI-1 in a manner that is at least partially independent of TFFB1, a gene associated with tissue fibrosis, or tissue damage.

"Delineation of the relationship between TGFB1 and PVT1 represents a critical component toward understanding the molecular mechanisms underlying the regulation of ECM in diabetic nephropathy," said Dr. Lucrecia Alvarez, the study's lead author and a TGen post-doctoral fellow.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Findings may help keep pancreatic disease off the menu
2. Saint Louis University findings: Dont pitch stockpiled avian flu vaccine
3. New findings in Indias Bt cotton controversy: Good for the field, bad for the farm?
4. New findings provide cost, benefit data for Florida citrus industry
5. Findings on pollution damage to human airways could yield new therapies
6. 23andMe presents top 10 most interesting genetic findings of 2010
7. Findings suggest new cause, possible treatment for multiple sclerosis
8. Biomedical and health professionals converge in D.C. to absorb new findings in science of informatics
9. Unexpected findings of lead exposure may lead to treating blindness
10. Gynecologist disputes findings
11. New findings pull back curtain on relationship between iron and Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: